Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MCLA-117 |
| Synonyms | |
| Therapy Description |
Tepoditamab (MCLA-117) is a bispecific antibody that targets CLEC12A and CD3, which potentially results in an increased T-cell response against CLEC12A-expressing tumor cells and tumor cell lysis (PMID: 31286786). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MCLA-117 | Tepoditamab|MCLA117|MCLA 117|anti-CLEC12A-CD3 bispecific antibody | CD3 Antibody 119 | Tepoditamab (MCLA-117) is a bispecific antibody that targets CLEC12A and CD3, which potentially results in an increased T-cell response against CLEC12A-expressing tumor cells and tumor cell lysis (PMID: 31286786). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03038230 | Phase I | MCLA-117 | MCLA-117 in Acute Myelogenous Leukemia | Terminated | USA | NLD | ITA | FRA | BEL | 0 |